Statement: One patient in the primary trial was observed vomiting blood.
Primary_evidence: Adverse Events 1:   Total: 12/66 (18.18%)   Palpitations * 1/66 (1.52%)   Haematemesis * 1/66 (1.52%)   Performance status decreased * 1/66 (1.52%)   Hepatic failure * 1/66 (1.52%)   Cellulitis * 1/66 (1.52%)   Device related infection * 1/66 (1.52%)   Pneumonia * 1/66 (1.52%)   Pneumonia pneumococcal * 1/66 (1.52%)   Femur fracture * 0/66 (0.00%)   Hypokalaemia * 1/66 (1.52%)   Back pain * 2/66 (3.03%)